EAM
KYMR icon

Eventide Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Eventide Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.8M Sell
504,210
-122,715
-20% -$10.5M 0.77% 39
2026
Q1 		$52.2M Buy
626,925
+495
+0.1% +$39.2K 0.86% 37
2025
Q4 		$48.7M Sell
626,430
-18,160
-3% -$1.23M 0.76% 37
2025
Q3 		$36.5M Buy
644,590
+81,600
+14% +$3.68M 0.6% 65
2025
Q2 		$24.6M Buy
562,990
+37,852
+7% +$1.3M 0.43% 82
2025
Q1 		$14.4M Buy
525,138
+69,410
+15% +$2.53M 0.29% 104
2024
Q4 		$18.3M Sell
455,728
-52,174
-10% -$2.36M 0.33% 96
2024
Q3 		$24M Buy
507,902
+45,803
+10% +$2.02M 0.41% 75
2024
Q2 		$13.8M Buy
462,099
+442,325
+2,237% +$15.3M 0.24% 110
2024
Q1 		$795K Buy
+19,774
New +$708K 0.01% 155

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Eventide Asset Management's KYMR Position: Q2 2026 in Review

Eventide Asset Management reduced its Kymera Therapeutics (KYMR) stake by 20% in Q2 2026, selling an estimated $10.5M and leaving 504,210 shares worth $57.8M. The position accounts for 0.77% of the portfolio, ranked #39.

Eventide Asset Management first reported a position in KYMR in Q1 2024 and has held it in 10 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Eventide Asset Management held 504,210 shares of Kymera Therapeutics worth $57.8M as of Q2 2026.
  • Eventide Asset Management sold 122,715 Kymera Therapeutics shares in Q2 2026, an estimated $10.5M.
  • Kymera Therapeutics made up 0.77% of Eventide Asset Management's portfolio in Q2 2026, its #39 holding.
  • Eventide Asset Management first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.